Welcome to our dedicated page for Mimedx Group SEC filings (Ticker: MDXG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
MiMedx Group, Inc. filings document the regulatory record for a Florida-incorporated regenerative biomaterials company serving wound care, burn and surgical healthcare markets. Form 8-K reports furnish quarterly and annual operating results, earnings materials, Regulation FD investor presentations and material events tied to business updates.
The company’s proxy materials cover board elections, executive compensation, equity-award valuation, pay-versus-performance data and shareholder voting matters. Recent current reports also document restructuring-related officer changes and temporary compensation reductions for named executive officers, linking governance disclosures to changes in the company’s cost structure.
Capper Joseph H reported acquisition or exercise transactions in this Form 4 filing.
MiMedx Group, Inc. Chief Executive Officer Joseph H. Capper reported equity awards consisting of stock options and restricted stock granted on March 4, 2026. He was awarded 310,574 stock options and 371,094 shares of common stock at a price of $0.00 per share.
The restricted stock grant vests fully on the third anniversary of the grant date, subject to his continued employment under a Restricted Stock Unit Agreement. The stock options vest in four equal annual installments of 25% on each anniversary of the grant date, also subject to continued employment.
MiMedx Group Chief Financial Officer Doug Rice received new equity awards in the form of stock options and restricted stock. On March 4, 2026, he was granted 62,068 stock options at an exercise price of $0.00 per share and 74,163 shares of common stock as a restricted stock grant.
The stock options vest in four equal annual installments of 25% on each anniversary of the grant date, contingent on his continued employment under the Nonqualified Stock Option Agreement. The restricted stock vests fully on the third anniversary of the grant date, also subject to continued employment under the Restricted Stock Unit Agreement.
Hulse William Frank IV reported acquisition or exercise transactions in this Form 4 filing.
MIMEDX GROUP, INC. General Counsel and Chief Administrative Officer William Frank Hulse IV reported equity awards on Common Stock and Stock Options. These are classified as grants or awards rather than open‑market purchases or sales.
The filing shows an award of 74,987 shares of Common Stock at a price per share of $0.0000, bringing his directly held Common Stock to 488,536 shares. According to the footnotes, this represents restricted stock that vests fully on the third anniversary of the grant, subject to his continued employment under the Restricted Stock Unit Agreement.
He also received Stock Options covering 62,758 shares at a price per share of $0.0000, increasing his directly held options to 171,190. The options vest 25% on each anniversary of the grant date, conditioned on his continued employment as described in the Nonqualified Stock Option Agreement.
MIMEDX GROUP, INC. Chief Operating Officer Ricci S. Whitlow reported equity awards on March 4, 2026. She acquired 62,068 stock options and 74,163 shares of restricted common stock at a price of $0.00 per share as compensation grants.
The restricted stock vests fully on the third anniversary of the grant, subject to continued employment. The options vest in four equal annual installments, each 25% on the grant-date anniversaries, also conditioned on continued employment. Following these grants, she directly holds 169,309 stock options and 462,825 common shares.
MIMEDX GROUP, INC. Chief Commercial Officer Kimberly Maersk-Moller reported equity awards on March 4, 2026. She was granted 62,068 stock options at an exercise price of $0.00 per share, increasing her directly held options to 137,862 following the grant.
She also received a grant of 74,163 shares of common stock at $0.00 per share, raising her directly held common shares to 314,637. Footnotes state the common stock grant consists of restricted stock that vests fully on the third anniversary of the grant, and that the options vest in 25% increments on each anniversary of the grant date, in both cases conditioned on continued employment.
MiMedx Group, Inc. reported record fourth-quarter and full-year 2025 results, with net sales of $118.1 million for the quarter, up 27% year-over-year, and $418.6 million for the year, up 20%. Growth was driven by Wound sales rising 28% in Q4 and Surgical sales up 25%, supported by new products like EPIXPRESS, EMERGE and strong AMNIOFIX and AMNIOEFFECT performance.
Fourth-quarter GAAP net income was $15.2 million, or $0.10 per diluted share, while Adjusted EBITDA reached $29.4 million, a 24.9% margin. For 2025, GAAP net income was $48.6 million and Adjusted EBITDA was $105.7 million, representing a 25.3% margin. Gross margin stayed above 82% on a GAAP basis and 85% on an adjusted basis for the year.
Cash and cash equivalents were $166.1 million at December 31, 2025, with net cash of $148 million after debt, up $63 million year-over-year. The board authorized a share repurchase program of up to $100 million over two years. For 2026, MiMedx estimates net sales of $340–360 million and expects an Adjusted EBITDA margin in the mid-to-high teens, reflecting anticipated Medicare reimbursement changes that may pressure near-term Wound revenue.
MiMedx Group, Inc. files its annual report describing a wound care and surgical biologics business built around placental allografts and a growing portfolio of animal‑derived and distributed products. The company focuses on chronic and hard‑to‑heal wounds and increasing use of its tissues in surgical procedures.
MiMedx highlights its PURION processing technology, extensive clinical evidence for products like EPIFIX, and expansion into xenografts with FDA 510(k)‑cleared HELIOGEN. It is also growing internationally, particularly in Japan, where EPIFIX is approved and reimbursed as a Class IV medical device.
The report notes significant Medicare reimbursement reforms for skin substitutes effective in 2026, which shift payment to a flat rate per square centimeter, creating potential pressure on industry economics. As of June 30, 2025, non‑affiliate market value was about $719 million, and 148,566,586 shares were outstanding as of February 19, 2026.
MiMedx Group Chief Operating Officer Ricci S. Whitlow reported a tax-related share disposition. On the vesting of restricted stock, 61,961 shares of common stock were withheld by the company to satisfy tax withholding requirements at $5.12 per share. After this transaction, Whitlow directly owns 388,662 shares of MiMedx Group common stock, which includes 1,675 shares previously acquired through the company’s Employee Stock Purchase Plan.
MiMedx Group, Inc. has a new ownership update from Trigran-affiliated investors. An amended Schedule 13G shows Trigran Investments, Inc. and related individuals collectively reporting beneficial ownership of 6,163,384 shares of MiMedx common stock, representing 4.2% of the outstanding class as of the reported date.
The group reports no sole voting or dispositive power, with shared voting power over 5,688,192 shares and shared dispositive power over 6,163,384 shares. The filers state the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of MiMedx.
MiMedx Group, Inc. filed a Form 8-K to share that it updated its investor presentation on January 12, 2026, furnishing the slide deck as Exhibit 99.1 under Regulation FD. The materials include forward-looking statements about future sales and sales growth, 2026 and longer-term financial goals such as net sales, Adjusted EBITDA, margins, corporate expenses and cash, as well as expectations for the placental tissue market, Medicare spending and growth across care settings. The company highlights numerous risks that could cause actual results to differ and notes it has no obligation to update these forward-looking statements after the date of the report.